Literature DB >> 9428928

Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications.

M Miettinen1, A J Kovatich, P Kärkkäinen.   

Abstract

Previous studies indicate that keratins 7, 8 and 18 are present in all thyroid papillary and follicular lesions, but the distribution of other keratins has been incompletely characterized. The profile of individual keratin (K) polypeptides was evaluated immunohistochemically in over 200 non-neoplastic and neoplastic thyroid papillary and follicular lesions. Monoclonal antibodies to K19, K17, K16, K5/6 and K10 were applied in paraffin sections of formaldehyde-fixed tissue. K19 was present variably, often only focally in goitres, and was present only sporadically in papillary hyperplasia. However, K19 was strongly and uniformly expressed in virtually all papillary carcinomas, indicating differential diagnostic usefulness in differentiating papillary hyperplasia and papillary carcinoma. About half of the follicular carcinomas (defined as tumours strictly excluding the follicular variant of papillary carcinoma) were also strongly K19-positive, suggesting that K19 patterns are not reliable in differentiating papillary and follicular carcinoma. K17 and K5/6 were present in cysts and squamous metaplasia of goitres, and focally in papillary but only exceptionally in follicular carcinoma in areas of squamous differentiation and tumour cells in desmoplastic stroma. K16 in turn was present only focally in well-developed squamous metaplasia in goitres but was not found in differentiated thyroid carcinomas. K10, a high-molecular-weight keratin typical of epidermal differentiation, was identified neither in non-neoplastic nor in neoplastic differentiated thyroid lesions, including squamous metaplasia. These results indicate that papillary carcinomas differ from other differentiated thyroid tumours in their varying, usually focal, expression of stratified epithelial keratins that are partly but not exclusively related to squamous differentiation in such lesions. However, papillary carcinomas do not express truly epidermally restricted keratins; their previously described reactivity with polyclonal "epidermal keratin" antibodies most probably results from the reactivity of such antibodies with K19.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9428928     DOI: 10.1007/s004280050117

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  10 in total

Review 1.  Best practice in thyroid pathology.

Authors:  C E Anderson; K M McLaren
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  Overexpression of cytokeratin 17 is associated with the development of papillary thyroid carcinoma and the presence of lymph node metastasis.

Authors:  Hyun-Soo Kim; Jeong-Ju Lee; Sung-Im Do; Kyungeun Kim; In-Gu Do; Dong-Hoon Kim; Seoung Wan Chae; Jin Hee Sohn
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Diagnostic and prognostic value of Stanniocalcin 1 expression in papillary thyroid cancer.

Authors:  Sevinç Sengun; Hakan Korkmaz; Metin Ciris; Ramazan Oguz Yüceer; Serife Mehtap Boyluboy; Mehmet Kiran
Journal:  Endocrine       Date:  2022-07-04       Impact factor: 3.925

4.  RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation.

Authors:  Eunah Shin; Woung Youn Chung; Woo Ick Yang; Cheong Soo Park; Soon Won Hong
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

5.  Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma.

Authors:  Lei Gong; Ping Chen; Xianjun Liu; Ying Han; Yanping Zhou; Weidong Zhang; Hong Li; Chuanjia Li; Jiang Xie
Journal:  Gland Surg       Date:  2012-05

6.  Tumor Susceptibility Gene 101 Mediates Anoikis Resistance of Metastatic Thyroid Cancer Cells.

Authors:  Kittirat Saharat; Kriengsak Lirdprapamongkol; Daranee Chokchaichamnankit; Chantragan Srisomsap; Jisnuson Svasti; N Monique Paricharttanakul
Journal:  Cancer Genomics Proteomics       Date:  2018 Nov-Dec       Impact factor: 4.069

7.  Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.

Authors:  Young Joo Park; Soo Heon Kwak; Dong Chul Kim; Haeryoung Kim; Gheeyoung Choe; Do Joon Park; Hak Chul Jang; Seong Hoe Park; Bo Youn Cho; So Yeon Park
Journal:  J Korean Med Sci       Date:  2007-08       Impact factor: 2.153

8.  Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein.

Authors:  Dehuang Guo; Qinqin Xu; Sarabjot Pabla; John Koomen; Paul Biddinger; Ashok Sharma; Simarjot Pabla; Rafal Pacholczyk; Chien-Chung Chang; Kevin Friedrich; Kamran Mohammed; Robert C Smallridge; John A Copland; Jin-Xiong She; Paul M Weinberger
Journal:  Int J Mol Sci       Date:  2018-02-14       Impact factor: 5.923

9.  Serum biomarkers of papillary thyroid cancer.

Authors:  Fawaz M Makki; S Mark Taylor; Ali Shahnavaz; Andrew Leslie; Jeffrey Gallant; Susan Douglas; Evelyn Teh; Jonathan Trites; Martin Bullock; Karen Inglis; Devanand M Pinto; Robert D Hart
Journal:  J Otolaryngol Head Neck Surg       Date:  2013-02-07

10.  Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma.

Authors:  Debdas Bose; Ram Narayan Das; Uttara Chatterjee; Uma Banerjee
Journal:  Indian J Med Paediatr Oncol       Date:  2012-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.